Insulin was discovered 100 years ago by a research team from University of Toronto, Canada consisting of Frederick Banting, Charles Best, J.J.R. MacLeod and James Bertram Collip. Consequently, Novo Nordisk and it´s predessors, Nordisk Insulin Laboratorium and Novo Terapeutisk Laboratorium have historically had strong ties to University of Toronto. These ties are now strenthened once again with the decision to invest DKK 200 million to establish the Novo Nordisk Network for Healthy Populations which will focus on new ways to support healthier urban populations and will draw on University of Toronto’s expertise in public health research and education programmes to impact the global fight against diabetes and other serious chronic diseases, according to the Novo Nordisk press release. Novo Nordisk’s is donating DKK 100 million (CAD 20 million) to the network which is being matched by U of T with further DKK 100 million in financial and in-kind contributions.
“One hundred years after the discovery of insulin, we’re proud to once again partner with the University of Toronto with the ambition of helping society to address the root causes of type 2 diabetes and obesity. As we recognize insulin’s success in saving millions of lives around the world, we are excited to expand our commitment towards the prevention of these serious chronic diseases.” says Lars Fruergaard Jørgensen, CEO and President of Novo Nordisk